Charles River Laboratories International (CRL) EBITDA Margin (2009 - 2026)
Charles River Laboratories International (CRL) posted quarterly EBITDA Margin of 28.51% for Q4 2025, down 1178.0% year-over-year from 2.64% in Q4 2024, and down 314.1% quarter-over-quarter from 13.32% in Q3 2025.
Charles River Laboratories International (CRL) EBITDA Margin (2009 - 2026) Analysis & Trends
Charles River Laboratories International's EBITDA Margin history runs 17 years deep, the most recent figure standing at 28.51% for Q4 2025.
- In Q4 2025, EBITDA Margin fell 1178.0% year-over-year to 28.51%; the TTM figure through Dec 2025 stood at 0.63% (down 499.0% YoY), while the FY2025 annual figure was 0.63%, down 499.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 28.51%, down from 13.32% in the prior quarter.
- The five-year high for EBITDA Margin was 19.26% in Q2 2022, with the low at 28.51% in Q4 2025.
- The 5-year median for EBITDA Margin is 14.84% (2022), against an average of 10.81%.
- The sharpest annual moves came in 2022 and 2024: EBITDA Margin soared 422 bps in 2022, then slumped 2984 bps in 2024.
- Charles River Laboratories International's EBITDA Margin stood at 19.09% in 2021, then fell by 22 bps to 14.89% in 2022, then decreased by 12 bps to 13.12% in 2023, then tumbled by 228 bps to 16.73% in 2024, then slumped by 70 bps to 28.51% in 2025.
- Business Quant data shows CRL's EBITDA Margin at 28.51% in Q4 2025, 13.32% in Q3 2025, and 9.7% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 17.40% |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | 17.99% |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | -10.07% |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 21.74% |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 11.58% |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 34.98% |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | 21.14% |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 31.97% |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 12.10% |
| 10 | Charles River Laboratories International | 14.28 Bn | 14.09 Bn | 452.07 Mn | 11.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 11.94% |
| Dec 27, 2025 | -28.51% |
| Sep 27, 2025 | 13.32% |
| Jun 28, 2025 | 9.70% |
| Mar 29, 2025 | 7.59% |
| Dec 28, 2024 | -16.73% |
| Sep 28, 2024 | 11.63% |
| Jun 29, 2024 | 14.78% |
| Mar 30, 2024 | 12.45% |
| Dec 30, 2023 | 13.12% |
| Sep 30, 2023 | 14.76% |
| Jul 1, 2023 | 15.56% |
| Apr 1, 2023 | 16.31% |
| Dec 31, 2022 | 14.89% |
| Sep 24, 2022 | 15.26% |
| Jun 25, 2022 | 19.26% |
| Mar 26, 2022 | 16.28% |
| Dec 25, 2021 | 19.09% |
| Sep 25, 2021 | 17.39% |
| Jun 26, 2021 | 15.04% |